Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] SUMMARY WITH CRITICAL APPRAISAL Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis 2 Context and Policy Issues Pimecrolimus 1% cream has an indication of “For short-term treatment and intermittent long-term therapy of mild to moderate atopic dermatitis in non-immunocompromised patients 2 years of age and older, in whom the use of alternative, conve [...] Due to the expanded clinical use of pimecrolimus, a review of both the evidence of its efficacy and of its potential economic evaluation is of importance for a more evidence- based clinical and policy decision making process. [...] None of the included systematic reviews provided a meta-analysis of a pooled estimate, instead a narrative synthesis of the results of the included studies was provided. [...] Outcomes The included systematic reviews attempted to capture any outcome in the studies related to investigator or patient assessment of the overall severity of the disease along with the severity of specific symptoms.